Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 11372
TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610502(BDBM610505 | US11713306, Example 17)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610550(US11713306, Example 48)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610549(US11713306, Example 32)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610548(US11713306, Example 16)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610547(US11713306, Example 43)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610546(US11713306, Example 27)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610545(US11713306, Example 11)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610509(US11713306, Example 35)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610501(US11713306, Example 1 | BDBM610504)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610508(US11713306, Example 19)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610507(US11713306, Example 3)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610503(BDBM610506 | US11713306, Example 33)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610501(US11713306, Example 1 | BDBM610504)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610503(BDBM610506 | US11713306, Example 33)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610502(BDBM610505 | US11713306, Example 17)
Affinity DataIC50: 10nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610530(US11713306, Example 26)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610531(US11713306, Example 42)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610510(BDBM610532 | US11713306, Example 4)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610511(US11713306, Example 20 | BDBM610533)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610512(BDBM610534 | US11713306, Example 36)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610535(US11713306, Example 13)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610536(US11713306, Example 29)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610537(US11713306, Example 45)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610538(US11713306, Example 14)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610539(US11713306, Example 30)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610540(US11713306, Example 46)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610541(US11713306, Example 15)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610542(US11713306, Example 31)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610544(US11713306, Example 47)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610513(US11713306, Example 5 | BDBM610519)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610510(BDBM610532 | US11713306, Example 4)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610511(US11713306, Example 20 | BDBM610533)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610512(BDBM610534 | US11713306, Example 36)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610513(US11713306, Example 5 | BDBM610519)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610514(US11713306, Example 21 | BDBM610520)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610515(BDBM610521 | US11713306, Example 37)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610516(US11713306, Example 6)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610517(US11713306, Example 22)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610518(US11713306, Example 38)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610529(US11713306, Example 10)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610514(US11713306, Example 21 | BDBM610520)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610515(BDBM610521 | US11713306, Example 37)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610522(US11713306, Example 8)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610523(US11713306, Example 24)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610525(US11713306, Example 40)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610526(US11713306, Example 9)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610527(US11713306, Example 25)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fyn(Human)
Wayshine Biopharm Holding

US Patent
LigandPNGBDBM610528(US11713306, Example 41)
Affinity DataIC50: 100nMAssay Description:2.5 times of the kinase (VEGFR2 or EGFR or FYN) buffer solution was added to the compound diluted in equal concentration in the 384-well plate and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
Go to US Patent